A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

NCT03375203 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

365

Enrollment

INDUSTRY

Sponsor class

Conditions

Insomnia Disorders

Interventions

DRUG: Placebo
DRUG: JNJ-42847922, 5 mg
DRUG: JNJ-42847922, 10 mg
DRUG: JNJ-42847922, 20 mg
DRUG: Zolpidem

Sponsor

Janssen Research & Development, LLC